Research shows that LRP6 deficiency can inhibit the Wnt/β-catenin signaling pathway in triple-negative breast cancer (TNBC) cells, which subsequently inhibits the migration and invasion of TNBC cells [11], while the upregulation of LRP6 expression in metastatic prostate cancer will increase the risk of recurrence [18]. This evidence concerns the gene LRP6 and metastatic prostate carcinoma.